Circassia Pharmaceuticals (LON:CIR)

Circassia Pharmaceuticals (LON:CIR)

Share Price
18.65 p
0.8 (4.48 %)
Market Cap
£0.70 m
Proactive Investors - Run By Investors For Investors

Circassia Pharmaceuticals

Circassia is a specialty pharmaceutical company focused on respiratory disease. Our growing commercial organization promotes our innovative asthma management products directly to specialist physicians in a number of key markets, and we market the chronic obstructive pulmonary disease (COPD) product Tudorza® in the United States. We are expanding our commercial platform in China, and are...

Market: LSE:CIR
52-week High/Low: 87.400p / 13.250p
Sector: Pharma & Biotech
Market Cap: £0.70 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Circassia Pharmaceuticals

Circassia Pharmaceuticals Snapshot

Our ambition is to become a leading specialty pharmaceutical company meeting the needs of patients around the world. With our portfolio of respiratory products we’re making good progress towards achieving our goal.


We currently market two respiratory-related products:

  1. NIOX® for use in asthma management.
  2. Tudorza® for the treatment of chronic obstructive pulmonary disease under our US commercial collaboration with AstraZeneca.




Circassia’s novel NIOX® products are used to assist asthma management around the world. The current generation, NIOX VERO®, is approved in a number of countries, and is available in many major markets including the US, EU, Japan and China. We market the products directly in the United States, United Kingdom and Germany and also provide NIOX® through an international network of distributors.

Monitoring airway inflammation – monitoring asthma

Allergic airway inflammation is the major underlying cause of asthma. NIOX® exploits the discovery that patients with allergic airway inflammation generally have higher than normal levels of nitric oxide in their exhaled breath. By measuring the concentration of this nitric oxide (the fractional exhaled nitric oxide or FeNO), clinicians can evaluate allergic airway inflammation in patients with underlying asthma.

As a result, NIOX® is used to improve asthma management by assisting in:

  • diagnosis
  • determining responsiveness to inhaled corticosteroids
  • tailoring inhaled steroid use
  • monitoring treatment compliance
  • reducing exacerbations.


NIOX® US Use and Risks Statement

NIOX VERO® measures Nitric Oxide (NO) in human breath. Nitric Oxide is frequently increased in some inflammatory processes such as asthma. The fractional NO concentration in expired breath (FeNO), can be measured by NIOX VERO according to guidelines for NO measurement established by the American Thoracic Society.

Measurement of FeNO by NIOX VERO is a quantitative, non-invasive, simple and safe method to measure the decrease in FeNO concentration in asthma patients that often occurs after treatment with anti-inflammatory pharmacological therapy, as an indication of the therapeutic effect in patients with elevated FeNO levels. NIOX VERO is suitable for children, approximately 7 – 17 years, and adults 18 years and older.

FeNO measurements provide the physician with means of evaluating an asthma patient’s response to anti-inflammatory therapy, as an adjunct to the established clinical and laboratory assessments in asthma. The NIOX VERO is intended for prescription use and should only be used as directed in the NIOX VERO User Manual by trained healthcare professionals. NIOX VERO cannot be used with infants or by children approximately under the age of 7, as measurement requires patient cooperation. NIOX VERO should not be used in critical care, emergency care or in anaesthesiology.




Tudorza® Pressair®

Circassia markets Tudorza® Pressair® in the United States as part of the company’s commercial collaboration with AstraZeneca. Tudorza® is indicated for the long-term, maintenance treatment of bronchospasm associated with COPD, including chronic bronchitis and emphysema. Tudorza® is presented as a dry powder formulation of the long-acting antimuscarinic agent (LAMA) aclidinium bromide, for administration twice daily by oral inhalation using the breath-actuated multi-dose dry powder inhaler, Pressair®.


Offices in UK, US, Sweden, China, and Germany.

Holders Name - Position - %

Invesco Ltd - 84,579,512 - 23.68%

AstraZeneca UK Ltd - 71,081,217 - 19.90%

Capital PLC - 58,225,647 - 16.30%

OppenheimerFunds Inc - 33,179,475 - 9.30%

Imperial Innovations Business LL - 26,494,875 - 7.42%

Neptune Investment Management Ltd - 26,438,471 - 7.40%

St James's Place PLC - 14,073,677 - 3.94%

VP BANK VADUZ - 6,138,657 - 1.73%

Woodford Investment Management Ltd - 5,048,259 - 1.41%

Aviva PLC - 4,540,889 - 1.27%

Legal & General Group PLC - 4,054,555 - 1.14%

Harris Steven Charles - 3,965,504 - 1.11%

Hargreaves Lansdown Asset Management - 2,402,822 - 0.67%

Circassia Pharmaceuticals PLC TR S - 2,355,207 - 0.66%

Merrill Lynch & Co Inc - 2,222,621 - 0.62%

Merrill Lynch Int Market Maker - 2,222,621 - 0.62%

Jane Harris - 1,993,548 - 0.56%

Swingland Charles Stuart Webb - 1,993,548 - 0.56%

Old Mutual PLC - 1,934,459 - 0.54%


Circassia Pharmaceuticals plc 
Northbrook House 
Robert Robinson Avenue 
The Oxford Science Park 
OX4 4GA 
United Kingdom 

Contact Details

+44 (0)1865 405560
+44 (0)7092 987560
General enquiries
Business development


Head office

Circassia Pharmaceuticals plc
Northbrook House
Robert Robinson Avenue
The Oxford Science Park
United Kingdom

Tel: +44 (0)1865 405560 Fax: +44 (0)7092 987560
General enquiries: [email protected] Investors: [email protected]

Registered office

The Magdalen Centre
Robert Robinson Avenue
The Oxford Science Park


Equiniti Limited
Aspect House
Spencer Road
Lancing West Sussex
United Kingdom
BN99 6DA

Shareholder support: 0371 384 2030 Calls to this number are charged at 8p per minute plus network extras. Lines are open 8:30am to 5:30pm Monday to Friday.


HSBC Bank plc
Apex Plaza


PricewaterhouseCoopers LLP
Chartered Accountants and Statutory Auditors
1 Embankment Place

Columns Including CIR


Market Reports Including CIR

Video RSS



© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use